“This study demonstrates that treatment with THC-rich cannabis in patients with mild to moderate UC is associated with clinical improvement.”
“In this study, we have demonstrated for the first time in a placebo-controlled trial that cannabinoid treatment has the potential to decrease disruptive behaviors associated with ASD, with acceptable tolerability.”
“We found that the legalization of recreational marijuana use in Colorado and Washington did not result in an increase in SUD [substance use disorder] treatment admissions for cocaine, opioids, or methamphetamines among adolescents or emerging adults.”
“Across the sample, individuals drank approximately 29 percent fewer drinks and were 2.06 times less likely to have a binge-drinking episode on days that cannabis was used compared with days cannabis was not used. These patterns were observed in males, females and the infrequent and frequent cannabis use groups.”
“Our study found that there is no link to marijuana use and an increase in cardiovascular disease. Furthermore, there may be a link between marijuana use and lowered risk of cardiovascular disease.”
“This study provides evidence that the types of cannabis available in recreational and medical cannabis dispensaries might hold promise as an alternative treatment for PTSD. … This study’s primary outcome supports the theory that cannabis should be [tested in clinical trials] as a potential therapeutic for PTSD.”
Since 2010, scientists have published over 23,000 peer-reviewed papers on cannabis, with the annual number of papers increasing every year.
For over five decades, federal regulators have only authorized a single licensee – the University of Mississippi – to cultivate cannabis plants for use in FDA-approved clinical studies.